Seattle Genetics licenses technology to GSK

12/21/2009 | Reuters

Seattle Genetics granted GlaxoSmithKline rights to use its antibody-drug conjugate technology. GSK will pay Seattle Genetics $12 million upfront and as much as $390 million in milestone fees if all ADC products created as a result of the deal reach the market.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD